Search

A study conducted by researchers at the University of Utah examined the efficacy of loncastuximab tesirine (lonca) following chimeric antigen receptor T-cell therapy (CAR-T) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in the USA. The study included 118 patients, with 95 receiving lonca following 2 L CAR-T and 23 following 3 L CAR-T. Results showed promising outcomes with lonca monotherapy in both 3 L and 4 L settings, including patients resistant to or progressing after CAR-T therapy. The study concluded that lonca was an effective treatment option for R/R DLBCL. [Extracted from the article]

A recent study conducted by the Institute of Oncology Research in Bellinzona, Switzerland, focused on the use of loncastuximab tesirine, an antibody-drug conjugate, in targeting CD19-positive lymphomas. The research found that loncastuximab tesirine demonstrated strong cytotoxic activity in B-cell lymphoma cell lines, with its efficacy correlated to CD19 expression levels. The study also identified potential synergistic effects when combining loncastuximab tesirine with other agents, such as BCL2 and PI3K inhibitors, suggesting its potential as a treatment option for patients with mature B-cell neoplasms. [Extracted from the article]

A recent study conducted by researchers from Peking University Cancer Hospital and Institute in China has found that loncastuximab tesirine (Lonca) shows promise as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study involved 64 Chinese patients who had failed two lines of systemic therapies and were treated with Lonca. The overall response rate (ORR) was 51.6%, with a complete response rate of 23.4%. The treatment was well-tolerated, although some patients experienced hematological events and other adverse events. The results of this study are consistent with a previous study conducted on white patients. [Extracted from the article]

A recent report from La Princesa University Hospital in Madrid, Spain discusses the use of loncastuximab tesirine in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). DLBCL is a type of cancer that affects B-cells, and many patients do not respond well to initial treatment. Loncastuximab tesirine is a new immunotherapy drug that has shown efficacy in refractory cases of DLBCL, with manageable side effects. The report explains the mechanism of action of the drug, its acceptance by the FDA, and potential new therapeutic options associated with its use. [Extracted from the article]

A recent report from the Institute of Oncology Research discusses the use of loncastuximab tesirine, an antibody-drug conjugate (ADC), in the treatment of CD19-positive lymphomas. Loncastuximab tesirine showed strong cytotoxic activity in B-cell lymphoma cell lines, and its effectiveness was correlated with CD19 expression levels and sensitivity to the ADC's warhead. The study also identified potential combination therapies, such as BCL2 and PI3K inhibitors, that could enhance the efficacy of loncastuximab tesirine. These findings support further development of loncastuximab tesirine as a single agent and in combination therapy for patients with mature B-cell neoplasms. [Extracted from the article]

Keywords: Seattle; State:Washington; United States; North and Central America; B-Cell Lymphoma; Cancer; Drugs and Therapies; Health and Medicine; Hematology; Immunologic Agents; Immunoproliferative Disorders; Large B-Cell Lymphoma; Loncastuximab Therapy; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Monoclonal Antibodies; Oncology; Pharmaceuticals EN Seattle State:Washington United States North and Central America B-Cell Lymphoma Cancer Drugs and Therapies Health and Medicine Hematology Immunologic Agents Immunoproliferative Disorders Large B-Cell Lymphoma Loncastuximab Therapy Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Monoclonal Antibodies Oncology Pharmaceuticals 1556 1556 1 06/19/23 20230620 NES 230620 2023 JUN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Oncology - B-Cell Lymphoma have been published. Keywords for this news article include: Seattle, Washington, United States, North and Central America, B-Cell Lymphoma, Cancer, Drugs and Therapies, Health and Medicine, Hematology, Immunologic Agents, Immunoproliferative Disorders, Large B-Cell Lymphoma, Loncastuximab Therapy, Lymphatic Diseases and Conditions, Lymphoma, Lymphoproliferative Disorders, Monoclonal Antibodies, Oncology, Pharmaceuticals, Department of Pharmacy. Seattle, State:Washington, United States, North and Central America, B-Cell Lymphoma, Cancer, Drugs and Therapies, Health and Medicine, Hematology, Immunologic Agents, Immunoproliferative Disorders, Loncastuximab Therapy, Lymphatic Diseases and Conditions, Lymphoma, Lymphoproliferative Disorders, Monoclonal Antibodies, Oncology, Pharmaceuticals, Large B-Cell Lymphoma. [Extracted from the article]

Researchers from Shanghai Jiao Tong University School of Medicine have conducted studies on antibody-drug conjugates (ADCs) for hematological malignancies. ADCs are targeted therapeutic drugs that combine monoclonal antibodies with cytotoxic drugs, showing promise in reducing damage to normal cells while effectively killing target cells. Current ADCs on the market in China and abroad have demonstrated good efficacy and safety, with ongoing clinical studies exploring new targets for treatment. The research highlights the potential of ADCs in advancing targeted immunotherapy for hematologic malignancies, with over a hundred ADCs in development globally. [Extracted from the article]